The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 18, 2021

Filed:

Dec. 16, 2016
Applicant:

The Johns Hopkins University, Baltimore, MD (US);

Inventors:

Seulki Lee, Elkridge, MD (US);

Martin G. Pomper, Baltimore, MD (US);

Jong-Sung Park, Elkridge, MD (US);

Yumin Oh, Elkridge, MD (US);

Magdalena Scully, Columbia, MD (US);

Maureen Horton, Baltimore, MD (US);

Assignee:

THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/19 (2006.01); A61K 31/25 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 47/60 (2017.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61P 37/06 (2006.01);
U.S. Cl.
CPC ...
A61K 38/191 (2013.01); A61K 38/177 (2013.01); A61K 39/39541 (2013.01); A61K 47/60 (2017.08); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); A61P 37/06 (2018.01); C07K 2317/21 (2013.01); C07K 2317/75 (2013.01);
Abstract

The present disclosure relates to methods and compositions for treating and/or preventing autoimmune fibrosis, such as systemic sclerosis (SSc; scleroderma). The method includes administering to a subject in need thereof an effective amount of a death receptor agonist. Suitable death receptor agonists include tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), agonistic death receptor antibodies, and variants, analogues, or derivatives thereof. The administration of the death receptor agonist blocks fibroblast or profibrogenic cell activation, and/or reduces or depletes myofibroblasts, thereby reducing or preventing systemic sclerosis.


Find Patent Forward Citations

Loading…